Andrey Semechkin, PhD.
Chief Executive Officer and Co-Chairman of the Board
Professor Semechkin is a specialist in system analysis, strategic planning and corporate management. He is a member of the Russian Academy of Sciences and has been Deputy Director of Institute of System Analysis since 2004. Professor Semechkin was awarded the Russian Government Award in Science and Technology in 2006 and has written several scientific books. He has over 20 years of experience creating and managing businesses across different industries and scientific sectors.
Mahnaz Ebrahimi, CPA
Chief Financial Officer
Ms. Ebrahimi has more than 25 years of experience in financial management and accounting of growing research-driven companies in the life sciences, biotechnology, and pharmaceutical sectors. Most recently, she has been assisting several biotechnology and technology companies on accounting and SEC related matters in an expert consultancy capacity, including Flux Power Holdings, Polaris Pharmaceuticals and Ocera Therapeutics. Ms. Ebrahimi served as Director of Finance and Planning, as well as Treasury, of eBioscience from 2010 until its acquisition by Affymetrix in June, 2012. She served as Vice President of Finance and Administration and Chief Financial Officer of Profil Institute for Clinical Research from 2003 to 2005. From 1989 to 2000, she served as Director of Finance & Treasury and Assistant Controller of Agouron Pharmaceuticals, which became a subsidiary of Pfizer in 2000.
Russell Kern, PhD.
Executive Vice President, Chief Scientific Officer
Dr. Kern was trained in medical genetics, embryology and stem cell biology. He holds a Ph.D. degree in Human Physiology from the Russian Academy of Medical Sciences and has broad expertise in neuroscience, and was part of the team, along with scientists from the NYU Medical School that elucidated the physiological changes that occur in the brains of Parkinson’s disease patients. Dr. Kern directs ISCO’s R&D programs including stem cell derivation, differentiation and the pre-clinical and clinical evaluation of stem cell derived cells and tissue. He has developed a general method of deriving highly pure populations of neural stem cells and dopaminergic neurons from pluripotent stems cells that is novel, practical and suitable for use in a clinical setting. Dr. Kern is a well-known speaker on stem cell biology, including the use of stem cells for neurology and skin regeneration. He has more than 40 publications in the field of Parkinson’s disease and stem cell biology and he is an active member of the American Academy of Neurology, the Society for Neuroscience and the International Society for Stem Cell Research.
President of Lifeline Cell Technology, LLC
Mr. Bustamante has over eighteen years of experience in Operations of Biotechnology companies. His experience includes senior management positions in the areas of manufacturing, procurement, planning, warehousing, distribution and project management. Mr. Bustamante has an excellent understanding of the manufacture and logistics of cell culture products, biological instruments, molecular biology kits and diagnostics. He has led key projects in the areas of manufacturing resource planning (MRP) systems implementation, ISO compliance and product development. His industry experience includes Clonetics, BioWhittaker (Cambrex), Digene and Meso Scale Diagnostics. Mr. Bustamante received his BS degree in Biology from the University of San Diego and his MBA degree from Frostburg State University. He has been with Lifeline Cell Technology since 2007.
Vice President, Legal Affairs & Operations
Ms. Garnette received her J.D. from the University of Miami School of Law and has experience in various aspects of corporate and biotechnology law, regulatory affairs, project management, and business operations. After joining the Company in March 2011, she has held a variety of business and legal roles, including in-house counsel, advisor to the CEO, and Vice Chairman of the Board of Directors for Lifeline Skin Care. Ms. Garnette holds a Bachelor’s degree in Economics from San Francisco State University and has worked in the finance industry prior to beginning her legal career.
Director of Quality Control
Mr Hammond has over eighteen years of experience developing human cell based products and the quality control systems critical for their manufacture. He created and implemented the quality control systems that were responsible for making Clonetics products world renown for consistency and reproducibility. These quality control systems are the standard for companies currently manufacturing human cell based products. Mr. Hammond is expert in the field of both serum-containing and serum-free media formulations and in the purification of human cells, fields critical for therapeutic applications of cell culture technology.
Glenn Sherman, PhD.
Director of Chemistry Manufacturing and Controls (CMC)
Dr. Sherman has over 20 years of experience in Regulatory Affairs. He worked as a primary microbiology reviewer at the US FDA where he lead pre-IND reviews in the Division of Antiviral Drug Products. After leaving the FDA Dr. Sherman held regulatory positions at Pfizer and Johnson & Johnson, where he was CMC regulatory lead for biologics products and successfully managed IND related activities for the biologics clinical, nonclinical and CMC teams. Dr. Sherman holds a PhD in Microbiology and Immunology from the University of North Carolina, Chapel Hill, NC.